RECEIVED

1	□ EXPEDITE	The second secon
	□ No Hearing Set	17 JAN -6 A10:44
2	☑ Hearing is Set	. ~
3	Date: December 16, 2016 Time: 9:00 a.m.	THURSTON J- S =
	Time: 9.00 a.m. The Honorable Gary Tabor	SUPERIOR COURTS E Z
4	The Honorable Gary Tabor	
		THURSTON Linda My. SUPERIOR COURTS ton Co.
5	14-2-02381-0	
6	ORGSJ Order Granting Summary Judg	ment Z B Z
١٥	930345	JAN -6 PM 1: 34 Inda Myhre Enlow ment
7		THURSTON COUNTY, WA Thurston County Clerk superior county Clerk
8	STA	TE OF WASHINGTON
9		COUNTY SUPERIOR COURT
10	STATE OF WASHINGTON,	
	Plaintiff,	NO. 14-2-02381-0
11	<u></u>	JUDGMENT SUMMARY, FINDINGS
12	v.	OF FACT, CONCLUSIONS OF LAW
12	ECOD DEMOCRACY ACTION!	AND FINAL JUDGMENT
13	FOOD DEMOCRACY ACTION! 8 FOOD DEMOCRACY ACTION!	uiu .
	YES ON I-522 COMMITTEE TO	
14	LABEL GMOS IN WASHINGTON	N,
15	Defendar	uto.
	Detelluar	us.
16		
17	JUDGMEN	NT SUMMARY (RCW 4.64.030)
18	A. JUDGMENT CREDITOR:	Plaintiff, STATE OF WASHINGTON
19	D	TOOD DELLOCAL CONTRACTOR ASSESSMENT
	B. JUDGMENT DEBTORS:	FOOD DEMOCRACY ACTION! and FOOD DEMOCRACY ACTION! YES ON I-522
20		COMMITTEE TO LABEL GMOS IN WASHINGTON
		COMMITTEE TO EADED GROS III WASHINGTON
21	C. PRINCIPAL JUDGMENT:	\$319,281.58 penalty in favor of the State
22	D DIFFED DOT	
	D. INTEREST:	No prejudgment interest is owed. Principal judgment
23		amount(s) due and owing shall not bear interest unless the principal judgment is unpaid by the due date specified
_		herein
24		
25	E. COSTS AND FEES:	\$ 90,590.20 as Reasonable Attorneys Fees
	•	\$ 325.00 as Costs of Trial \$ 2,131.32 as Costs of Investigation
26		φ 2,131.32 as Costs of investigation
- 11		I I

F. ATTORNEYS FOR JUDGMENT CREDITOR Attorney General LINDA A. DALTON, WSBA No. 15467 Senior Assistant Attorney General CHAD C. STANDIFER, WSBA No. 29724 Assistant Attorney General

G. ATTORNEYS FOR JUDGMENT DEBTORS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

None appeared at trial

THIS MATTER came before the Court for trial on November 21, 2016. Plaintiff STATE OF WASHINGTON, appeared by and through its counsel, ROBERT W. FERGUSON, Attorney General, LINDA A. DALTON, Senior Assistant Attorney General, and CHAD C. STANDIFER, Assistant Attorney General. Defendants Food Democracy Action! (FDA) and Food Democracy Action! Yes on I-522 Committee to Label GMOs in Washington (FDA PAC) did not appear. This matter was originally set for trial on September 19, 2016. Defendants counsel withdrew from the case effective August 20, 2016. Shortly before trial, principals for the Defendants requested by email correspondence a continuance to secure new counsel. The Court continued this matter to November 21, 2016. On the eve of trial, the same individuals sought to continue the trial again but did not make any motion to the court. The matter proceeded to trial on November 21, 2016 and no one appeared for Defendants. The Court considered the exhibits admitted by the Court and evidence presented by the State, the testimony of Tony Perkins and Evelyn Lopez for the State, and the State's closing argument, along with the records and files in this case. Based on this evidence and testimony, the Court issues the following Findings of Fact.

I. FINDINGS OF FACT

1. Defendant Food Democracy Action! (FDA) is registered with the Internal Revenue Service as a 501(c)(4) non-profit organization. It was founded in April 2012. Its base of operations is in Clear Lake, Iowa. (Trial Exhibit 9).

25 | ///

26 | //

1	2.	Defendant Food Democracy Action! Yes on I-522 Committee to Label GMOs in
2		Washington (FDA PAC) is a registered political committee in Washington. It filed its
3		registration form on November 13, 2013. (Trial Exhibit 7).
4	3.	At all times relevant to this lawsuit, FDA's President and Treasurer was William D.
5		(David) Murphy.
6	4.	At all times relevant to this lawsuit, FDA PAC's Campaign Manager/Media Contact and
7		Committee Chair was David Murphy. Its Secretary/Treasurer was Lisa Stokke. (Trial
8		Exhibit 7).
9	5.	Prior to participating in the 2013 Initiative 522 election in Washington, FDA participated in
10		lobbying activities in the states of Connecticut and Maine as evidenced by their
11		solicitations to their members/supporters. (Trial Exhibit 5).
12	6.	During 2012, FDA actively participated in supporting a California ballot measure (Prop 37)
13		that, if passed, would have required labeling packaged food products to identify GMOs
14		(genetically modified organisms).
15	7.	FDA made at least two contributions in its own name totaling \$115,000 to support Prop 37.
16		These contributions were reported by the Yes on 37 for Your Right to Know political
17		committee as coming from FDA. (Trial Exhibit 2).
18	8.	In November 2012, California voters rejected Prop 37. (Trial Exhibit 3).
19	9.	On June 29, 2012, Chris and Leah McManus submitted Initiative 522 to the Washington
20		Secretary of State as an initiative to the legislature. Initiative 522 would have "require[d]
21		most raw agricultural commodities, processed foods, and seeds and seed stocks, if
22		produced using genetic engineering as defined, to be labeled as genetically engineered
23		when offered for retail sale."
24	10.	Initiative 522 appeared on the November 2013 General Election statewide ballot.
25		Washington voters rejected Initiative 522.
26		
ı		

2	Exhibit 5).	
3	12. Starting in July 2013, FDA sent four newsletters seeking money from its members and	
4	supporters to support the GMO labeling efforts in Washington, including Initiative 522.	
5	FDA labeled these efforts as a fundraising campaign to raise and receive money to support	
6	Initiative 522. (Trial Exhibits 5, 6)	
7	13. FDA sent three solicitations for contributions in July 2013. (Trial Exhibit 5). It sent a	
8	similar request in October 2013. (Trial Exhibit 6).	
9	14. Based on the date of the first solicitation, FDA and FDA PAC should have registered a	
10	political committee no later than August 13, 2013.	
11	15. FDA members and supporters began sending FDA money on July 30, 2013 and continued	
12	contributing money through November 1, 2013. (Trial Exhibit 10).	
13	16. FDA raised \$295,661.58 in cash and in-kind contributions to support Initiative 522. (Trial	
14	Exhibit 15).	
15	17. Of the money received, FDA and FDA PAC contributed \$200,000 in cash contributions to	
16	the Yes on I-522 political committee. Those contributions were made on the following	
17	dates in the identified amounts:	
18	a. August 16, 2013 - \$50,000	
19	b. October 15, 2013 - \$50,000	
20	c. October 24, 2013 - \$50,000	
21	d. October 25, 2013 - \$25,000	
22	e. October 30, 2013 - \$25,000.	
23	(Trial Exhibits 12, 14, 15).	
24	18. FDA reported itself as the source of these contributions. FDA received the money to make	
25	these contributions as a result of a direct solicitation to its members and supporters. FDA	
26	and FDA PAC received a total of \$250,036 in cash contributions. (Trial Exhibits 8, 9).	

1 || 11. In 2013, FDA and FDA PAC became aware of Initiative 522 in Washington. (Trial

1	19. FDA and FDA PAC also eventually reported FDA's making and FDA PAC's receipt of
2	in-kind contributions in the amount of \$45,627.13 as data services. (Trial Exhibits 11, 12,
3	13, 14, 15).
4	20. FDA and FDA PAC did not file any reports of contributions received until November 22,
5	2013. On that day, they filed 12 such reports, known as Form C3 reports. (Trial Exhibit
6	10).
7	21. FDA and FDA PAC's C3 reports were a total of 541 days late.
8	22. FDA and FDA PAC did not file any summary reports of expenditures until January 15,
9	2014. On that day, they filed five such reports, known as Form C4 reports. (Trial Exhibits
10	11, 12, 13, 14, 15).
11	23. FDA and FDA PAC's C4 reports were a total of 491 days late.
12	24. FDA did not register with the PDC as a political committee until November 13, 2013.
13	(Trial Exhibit 7). Based on FDA's solicitation of contributions and the Court's decision on
14	when the committee was formed, FDA's committee registration form should have been
15	filed no later than August 13, 2013. FDA filed its committee registration form 120 days
16	late.
17	25. FDA and FDA PAC failed to timely file 18 registration and disclosure reports in
18	accordance with state law.
19	26. FDA and FDA PAC admitted their failure to comply with state campaign finance
20	disclosure laws. (Trial Exhibits 8, 9; Answer to Complaint filed February 17, 2014).
21	27. The Public Disclosure Commission (PDC) makes information available to filers about what
22	and how to file disclosure reports. That information is available through the PDC website
23	as well as PDC compliance staff available to answer questions.
24	28. The purpose of the state's campaign finance disclosure laws is established in RCW
25	42.17A.001 and includes the aim of complete disclosure to "assure continuing public
26	confidence of fairness of elections" and to protect the public interest.

9	the website, how to find reporting materials, and about campaign finance data.
10	31. From July 2, 2013 to November 22, 2013, FDA and FDA PAC did not submit any political
11	committee finance disclosure reports that would have included and identified donors to
12	FDA PAC (Form C3 reports). Under state law, FDA and FDA PAC were obligated to file
13	reports of the contributions expected to and received from their members and supporters.
14	This amounted to at least 12 C3 reports that FDA and FDA PAC did not timely or properly
15	file.
16	32. FDA and FDA PAC did not disclose the contributors to FDA PAC until November 22,
17	2013.
18	33. Based on the reports eventually filed by FDA PAC, FDA and FDA PAC's contribution
19	reports were a cumulative total of 541 days late.
20	34. From July 2, 2013 to January 15, 2014, FDA and FDA PAC did not file any political
21	committee finance disclosure reports showing expenditures made from FDA PAC. Under
22	state law, FDA and FDA PAC should have filed summaries of financial activity (Form C4
23	reports) including five C4 reports through the end of December 2013. FDA and FDA PAC
24	did not file any reports for activity until January 15, 2014.
25	35. FDA and FDA PAC filed a final committee report with the state PDC on January 15,
26	2014.
1	. ·

1	36. Based on the reports eventually filed by FDA PAC, FDA and FDA PAC's expenditure
2	summary reports were a cumulative total of 491 days late.
3	37. FDA and FDA PAC failed to timely and properly disclose \$295,661.58 in contributions
4	received during 2013.
5	II. CONCLUSIONS OF LAW
6	Based on the Findings of Fact identified above, the Court makes the following
7	Conclusions of Law:
8	1. The totality of the record establishes under a preponderance of the evidence, as well as the
9	higher clear, cogent and convincing standard, that Defendants FDA and FDA PAC
10	solicited and received campaign contributions from its members and supporters, which they
11	used to fund contributions to support the 2013 Washington ballot measure, Initiative 522.
12	2. The totality of the record establishes under a preponderance of the evidence, as well as the
13	higher clear, cogent and convincing standard, that FDA formed a political committee as
14	defined by RCW 42.17A.005(37) as a receiver of contributions no later than July 30, 2013,
15	by creating an expectation of receiving contributions through the use of FDA's July
16	newsletters.
17	3. The totality of the record establishes under a preponderance of the evidence, as well as the
18	higher clear, cogent and convincing standard, that FDA and FDA PAC committed multiple
19	violations of Washington's campaign finance disclosure laws by:
20	a. Failing to file a C1pc form and timely register FDA PAC with the PDC as a
21	political committee in violation of RCW 42.17A.205;
22	b. Failing to timely identify a treasurer and bank account for FDA PAC in violation of
23	RCW 42.17A.210 and RCW 42.17A.215;
24	c. Failing to timely and properly file 17 reports of contributions received from its
25	members and supporters and expenditures made from those contributions in
26	violation of RCW 42.17A.235 and .240; and

d. Concealing the true sources of the contributions received and expenditures made in

1